Oklo stock tumbles as Financial Times scrutinizes valuation
Investing.com - H.C. Wainwright has reiterated its Buy rating and $12.00 price target on Fulcrum Therapeutics (NASDAQ:FULC), which has seen its shares surge over 156% in the past year, following the company’s presentation of preclinical data for its EED inhibitor at ESMO 2025. According to InvestingPro data, analyst targets for FULC range from $5 to $16, with the stock currently trading at $8.99.
The data presented this past weekend showcased FTX-6274, an orally available small-molecule inhibitor of EED with high selectivity and potency (Kd = 0.3 nM). The compound demonstrates favorable preclinical cross-species pharmacokinetics, low efflux liability, and low drug-drug interaction risk. InvestingPro analysis shows the company maintains a strong financial position with more cash than debt and a healthy current ratio of 24.42.
FTX-6274 exhibited encouraging single-agent efficacy in preclinical models, controlling tumor growth in LNCaP and C4-2 prostate cancer xenografts (72% and 98% tumor growth inhibition, respectively) at 30 mg/kg BID. These results compared favorably with enzalutamide (82% TGI at 20 mg/kg QD) and mevrometostat (97% TGI at 300 mg/kg BID).
The compound extended median survival by 53% versus mevrometostat (24.5 days vs. 16 days) in 22Rv1 xenograft models of enzalutamide-resistant mice. ELISA data from tumor samples confirmed on-target activity through reduced H3K27me3 levels, consistent with the drug’s mechanism of action.
H.C. Wainwright views FTX-6274 as offering long-term upside potential to complement Fulcrum’s lead asset pociredir in sickle cell disease (SCD), supporting the firm’s maintained Buy rating and $12 price target. Investors should note that Fulcrum’s next earnings report is scheduled for November 12, 2025. For deeper insights into FULC’s valuation and 12+ additional ProTips, visit InvestingPro.
In other recent news, Fulcrum Therapeutics has received significant attention from several analyst firms following its developments in sickle cell disease (SCD) treatment. RBC Capital raised its price target for the company to $5.00 from $4.00 after reviewing second-quarter results that showed an 8.6% increase in fetal hemoglobin levels with its drug pociredir at a 12 mg dose. H.C. Wainwright also upgraded Fulcrum Therapeutics from Neutral to Buy, citing promising data from the PIONEER Phase 1b trial, which demonstrated increases in fetal hemoglobin and improvements in key hematologic parameters. Meanwhile, Leerink Partners elevated its price target to $16.00, maintaining an Outperform rating due to the potential of pociredir as the company approaches a key milestone with Phase 1b data expected by the end of 2025.
Additionally, Cantor Fitzgerald reiterated its Overweight rating and $15.00 price target, highlighting data showing a correlation between increased fetal hemoglobin levels and reduced vaso-occlusive crisis rates in SCD patients. Oppenheimer also maintained its Outperform rating with a $15.00 price target, viewing upcoming pociredir data as an additional benefit rather than a critical event, given the drug’s previously demonstrated properties. These developments underscore the growing interest in Fulcrum Therapeutics’ progress in addressing sickle cell disease.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.